Employment Type : Full-Time
About Avadel Pharmaceuticals plc The Field Support Coordinator provides administrative support to remote sales department members including the VP of Sales, VP Market Access, and Executive Director of Patient Services as well as Regional Business Directors and Territory Business Managers and works collaboratively with colleagues. The Field Support Coordinator must maintain a decidedly customer focused perspective, be results driven and possess the ability learn fast and adjust to change quickly. They will be responsible for processes related to purchasing, meeting planning, expense reporting and calendar management. Essential Functions: Experience and Qualifications: Minimum Requirements:
At Avadel, we are passionately committed to providing solutions for overlooked and unmet medical needs through patient-focused, innovative products. We are thoughtful in our approach to identifying patient needs and finding better ways to serve them. Our organization fosters our culture based on being relentless for patients, having confidence with humility, being courageous, taking insight to action and togetherness. Success for us is defined through how we improve the lives of patients and how we achieve our objectives as ONE Team.
Our approach to developing new medicines is based on applying proprietary, drug delivery technology that improves the way drugs are dosed and released. We are currently focused on the development and potential FDA approval of our lead candidate, FT218.
Avadel’s FT218 is an investigational, once at bedtime, extended-release formulation of sodium oxybate intended to treat excessive daytime sleepiness (EDS) and cataplexy in patients suffering from narcolepsy. Sodium Oxybate is currently the standard of care for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients suffering from narcolepsy. However, the currently approved sodium oxybate formulations require two nightly doses - one dose at bedtime and the second dose 2.5-4 hours later, in the middle of the night.
Once at bedtime FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that once at bedtime FT218 may be clinically superior to a formulation of sodium oxybate that is already approved by the FDA for the same indication. In particular, once at bedtime FT218 may be safer due to ramifications associated with the dosing regimen of the currently marketed twice-nightly product. Avadel’s market research suggests that FT218, if approved by the FDA, has the potential to command a meaningful share of the multi-billion dollar narcolepsy treatment market. FT218 currently has patent protection until at least 2037 with additional patent applications pending that could extend that date beyond 2040.
On April 27, 2020, we announced positive topline results from our pivotal phase 3 REST-ON trial of once-nightly FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. On December 16, 2020, we announced the submission of our New Drug Application (NDA) in the United States for FT218. On March 1, 2021, we announced FDA acceptance of the FT218 NDA and a target action PDUFA date of October 15, 2021.
We are a small team that will be growing a lot and we have a lot of work to do in building towards our best-in-class team to support commercialization of FT218, if approved. We are seeking bright people who want to roll up their sleeves, build our company together and make an impact so that we can help people suffering from narcolepsy.
Position Summary:
For the health and safety of our employees, customers, and community, vaccination against COVID-19 is required as a condition of employment for this position and you must provide valid proof of vaccination.
Avadel is an Equal Opportunity Employer